Cystic fibrosis related diabetes

Abstract

Cystic fibrosis related diabetes is the most common co-morbidity in cystic fibrosis. Insulin deficiency is the key factor in the development of cystic fibrosis related diabetes, which is associated with worse pulmonary and nutritional morbidity and increased mortality. The oral glucose tolerance test remains standard for screening, but continuous glucose monitoring systems are increasingly used to help with screening and management. Insulin is the only treatment with evidence of benefit. The timing of insulin treatment, and the level of glycaemia for which to aim, are areas which need further research. Treatment is aimed at both optimising nutrition and lung function and reducing the risk of microvascular complications. Copyright © 2010 John Wiley & Sons.